Overview
Public Biotech
Formed from the merger of ATAI Life Sciences and Beckley Psytech in November 2025. Developing BPL-003 (mebufotenin/5-MeO-DMT nasal spray) for treatment-resistant depression, with Phase 3 trials expected Q2 2026.
Visit WebsiteBerlin, Germany
$600M
Market Cap
2018
Founded
120
Employees
0
Open Roles
Open Positions
No open positions at this time
Clinical Pipeline
No clinical trials on record